<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40943477</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>17</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8558</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms26178558</ELocationID><Abstract><AbstractText>Type 1 diabetes (T1D) is a chronic condition with an increasing prevalence worldwide and a significant improvement in life expectancy in the last decades. T1D confers an increased risk of cardiovascular events, driven by elevated LDL cholesterol (LDL-C) and qualitative lipoprotein abnormalities, such as dysfunctional HDL and smaller, denser LDL-C. Lipid-lowering outcome trials have overwhelmingly focused on type 2 diabetes or the general population, resulting in very limited T1D-specific evidence. Recommendations from major medical associations (ADA, ESC/EAS, ACC/AHA, ISPAD) create additional ambiguity regarding the treatment of dyslipidemia in T1D. This review synthesizes the available evidence on dyslipidemia management in T1D, including published observational cohorts, randomized controlled trials, and international guideline recommendations from January 2000 to June 2025. LDL-C remains the primary modifiable risk factor. Each 1 mmol/L increase is associated with 35-50% greater cardiovascular (CV) risk in T1D cohorts. Statin therapy reduces CV risk by up to 25% in patients with diabetes; however, evidence remains limited in patients with T1D. Ezetimibe provides an additional 18% LDL-C lowering and a 14% event reduction in mixed-diabetes trials, while PCSK9 inhibitors offer a potent 40-60% LDL-C reduction and an 18% MACE reduction. The uptake of statins in eligible adults with T1D remains below 50%. Statins remain the cornerstone of dyslipidemia management in T1D, with emerging evidence supporting ezetimibe and PCSK9 inhibitors. The heterogeneity across international guidelines and the scarcity of T1D-specific outcome data underscore the need for targeted research and evidence-based strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elian</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9537-8051</Identifier><AffiliationInfo><Affiliation>Diabetes, Nutrition and Metabolic Disease Unit, University of Medicine and Pharmacy Carol Davila, 5-7 Ion Movila Street, 0202475 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diabetes, Nutrition and Metabolic Disease Unit, National Institute of Diabetes, Nutrition and Metabolic Disease Prof. N. C. Paulescu, 020475 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorita</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Diabetes, Nutrition and Metabolic Disease Unit, National Institute of Diabetes, Nutrition and Metabolic Disease Prof. N. C. Paulescu, 020475 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stegaru</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Diabetes, Nutrition and Metabolic Disease Unit, University of Medicine and Pharmacy Carol Davila, 5-7 Ion Movila Street, 0202475 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diabetes, Nutrition and Metabolic Disease Unit, National Institute of Diabetes, Nutrition and Metabolic Disease Prof. N. C. Paulescu, 020475 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinereanu</LastName><ForeName>Dragos</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9054-8779</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Cardiovascular Surgery, University of Medicine and Pharmacy Carol Davila, 169 Splaiul Independen&#x21b;ei, 050098 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University and Emergency Hospital, 050098 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SEARCH-Vasc Centre of Excellence, 050098 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Publish not Perish</GrantID><Agency>Carol Davila University of Medicine and Pharmacy</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PCSK9 inhibitors</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">clinical guidelines</Keyword><Keyword MajorTopicYN="N">dyslipidemia</Keyword><Keyword MajorTopicYN="N">ezetimibe</Keyword><Keyword MajorTopicYN="N">lipid-lowering therapy</Keyword><Keyword MajorTopicYN="N">statins</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40943477</ArticleId><ArticleId IdType="pmc">PMC12428817</ArticleId><ArticleId IdType="doi">10.3390/ijms26178558</ArticleId><ArticleId IdType="pii">ijms26178558</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ogle G.D., Wang F., Haynes A., Gregory G.A., King T.W., Deng K., Dabelea D., James S., Jenkins A.J., Li X., et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res. Clin. Pract. 2025;225:112277. doi: 10.1016/j.diabres.2025.112277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2025.112277</ArticleId><ArticleId IdType="pubmed">40412624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tell S., Nadeau K.J., Eckel R.H. Lipid management for cardiovascular risk reduction in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27:207&#x2013;214. doi: 10.1097/MED.0000000000000551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MED.0000000000000551</ArticleId><ArticleId IdType="pmc">PMC7585932</ArticleId><ArticleId IdType="pubmed">32618632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chait A., Eckel R.H., Vrablik M., Zambon A. Lipid-lowering in diabetes: An update. Atherosclerosis. 2024;394:117313. doi: 10.1016/j.atherosclerosis.2023.117313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2023.117313</ArticleId><ArticleId IdType="pubmed">37945448</ArticleId></ArticleIdList></Reference><Reference><Citation>Verg&#xe8;s B. Lipid disorders in type 1 diabetes. Diabetes Metab. 2009;35:353&#x2013;360. doi: 10.1016/j.diabet.2009.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2009.04.004</ArticleId><ArticleId IdType="pubmed">19733492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Parhofer K.G. Diabetic dyslipidemia. Metabolism. 2014;63:1469&#x2013;1479. doi: 10.1016/j.metabol.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.08.010</ArticleId><ArticleId IdType="pubmed">25242435</ArticleId></ArticleIdList></Reference><Reference><Citation>Taskinen M.R. Diabetic dyslipidemia: From basic research to clinical practice. Diabetologia. 2003;46:733&#x2013;749. doi: 10.1007/s00125-003-1111-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-003-1111-y</ArticleId><ArticleId IdType="pubmed">12774165</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell. 2000;6:77&#x2013;86. doi: 10.1016/S1097-2765(05)00010-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(05)00010-9</ArticleId><ArticleId IdType="pubmed">10949029</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54:1615&#x2013;1625. doi: 10.2337/diabetes.54.6.1615.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.6.1615</ArticleId><ArticleId IdType="pubmed">15919781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 2010;106:842&#x2013;853. doi: 10.1161/CIRCRESAHA.109.212217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.109.212217</ArticleId><ArticleId IdType="pmc">PMC2862596</ArticleId><ArticleId IdType="pubmed">20299674</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002;23:599&#x2013;622. doi: 10.1210/er.2001-0039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2001-0039</ArticleId><ArticleId IdType="pubmed">12372842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagareddy P.R., Murphy A.J., Stirzaker R.A., Hu Y., Yu S., Miller R.G., Ramkhelawon B., Distel E., Westerterp M., Huang L.S., et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17:695&#x2013;708. doi: 10.1016/j.cmet.2013.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.04.001</ArticleId><ArticleId IdType="pmc">PMC3992275</ArticleId><ArticleId IdType="pubmed">23663738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagareddy P.R., Kraakman M., Masters S.L., Stirzaker R.A., Gorman D.J., Grant R.W., Dragoljevic D., Hong E.S., Abdel-Latif A., Smyth S.S., et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014;19:821&#x2013;835. doi: 10.1016/j.cmet.2014.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.03.029</ArticleId><ArticleId IdType="pmc">PMC4048939</ArticleId><ArticleId IdType="pubmed">24807222</ArticleId></ArticleIdList></Reference><Reference><Citation>Maahs D.M., Daniels S.R., de Ferranti S.D., Dichek H.L., Flynn J., Goldstein B.I., Kelly A.S., Nadeau K.J., Martyn-Nemeth P., Osganian S.K., et al. Cardiovascular disease risk factors in youth with diabetes mellitus: A scientific statement from the American Heart Association. Circulation. 2014;130:1532&#x2013;1558. doi: 10.1161/CIR.0000000000000094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000094</ArticleId><ArticleId IdType="pubmed">25170098</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A., Caixas A., Carreras G., Mauricio D., Pou J.M., Serrat J., G&#xf3;mez-Gerique J., de Leiva A. Lipoprotein compositional abnormalities in type I diabetes: Effect of improved glycaemic control. Diabetes Res. Clin. Pract. 1997;36:83&#x2013;90. doi: 10.1016/S0168-8227(97)00033-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8227(97)00033-8</ArticleId><ArticleId IdType="pubmed">9229192</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawshani A., Rawshani A., Sattar N., Franz&#xe9;n S., McGuire D.K., Eliasson B., Svensson A.M., Zethelius B., Miftaraj M., Rosengren A., et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2019;139:1900&#x2013;1912. doi: 10.1161/CIRCULATIONAHA.118.037454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.037454</ArticleId><ArticleId IdType="pubmed">30798638</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan D.M., DCCT/EDIC Research Group The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014;37:9&#x2013;16. doi: 10.2337/dc13-2112.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-2112</ArticleId><ArticleId IdType="pmc">PMC3867999</ArticleId><ArticleId IdType="pubmed">24356592</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Costacou T., Orchard T.J. Risk factor modeling for cardiovascular disease in type 1 diabetes in the pittsburgh epidemiology of diabetes complications (EDC) study: A comparison with the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC) Diabetes. 2019;68:409&#x2013;419. doi: 10.2337/DB18-0515.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DB18-0515</ArticleId><ArticleId IdType="pmc">PMC6341302</ArticleId><ArticleId IdType="pubmed">30409781</ArticleId></ArticleIdList></Reference><Reference><Citation>Orchard T.J., Forrest K.Y.Z., Kuller L.H., Becker D.J. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the pittsburgh epidemiology of diabetes complications study. Diabetes Care. 2001;24:1053&#x2013;1059. doi: 10.2337/diacare.24.6.1053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.24.6.1053</ArticleId><ArticleId IdType="pubmed">11375370</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association  Standards of Care in Diabetes.  [(accessed on 26 June 2025)].  Available online:  https://professional.diabetes.org/standards-of-care.</Citation></Reference><Reference><Citation>Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S., Faiella-Tommasino J., Forman D.E., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary Circulation. J. Am. Coll. Cardiol. 2019;73:3168&#x2013;3209. doi: 10.1016/j.jacc.2018.11.002. Correction in J. Am. Coll. Cardiol. 2024, 84, 1772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.002</ArticleId><ArticleId IdType="pubmed">30423391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahleova H., Znayenko-Miller T., Smith K., Khambatta C., Barbaro R., Sutton M., Holtz D.N., Sklar M., Pineda D., Holubkov R., et al. Effect of a Dietary Intervention on Insulin Requirements and Glycemic Control in Type 1 Diabetes: A 12-Week Randomized Clinical Trial. Clin. Diabetes. 2024;42:419&#x2013;427. doi: 10.2337/cd23-0086.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/cd23-0086</ArticleId><ArticleId IdType="pmc">PMC11247033</ArticleId><ArticleId IdType="pubmed">39015168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaacks L.M., Liu W., Ji L., Mendez M.A., Du S., Crandell J., Rosamond W., Mayer-Davis E.J. Diabetes nutrition therapy and dietary intake among individuals with Type 1 diabetes in China. Diabet. Med. 2015;32:399&#x2013;406. doi: 10.1111/dme.12634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.12634</ArticleId><ArticleId IdType="pmc">PMC4329062</ArticleId><ArticleId IdType="pubmed">25407093</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M.C., Moran J., Forsblom C., Harjutsalo V., Thorn L., Ahola A., Wad&#xe9;n J., Tolonen N., Saraheimo M., Gordin D., et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861&#x2013;866. doi: 10.2337/dc10-1722.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc10-1722</ArticleId><ArticleId IdType="pmc">PMC3064042</ArticleId><ArticleId IdType="pubmed">21307382</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun H.M., Betteridge D.J., Durrington P.N., A Hitman G., Neil H.A.W., Livingstone S.J., Thomason M.J., I Mackness M., Charlton-Menys V., Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685&#x2013;696. doi: 10.1016/S0140-6736(04)16895-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16895-5</ArticleId><ArticleId IdType="pubmed">15325833</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R., Armitage J., Parish S., Sleight P., Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet. 2002;360:7&#x2013;22. doi: 10.1016/S0140-6736(02)09327-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)09327-3</ArticleId><ArticleId IdType="pubmed">12114036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholesterol Treatment Trialists&#x2019; (CTT) Collaborators. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., Armitage J., Baigent C. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117&#x2013;125. doi: 10.1016/s0140-6736(08)60104-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(08)60104-x</ArticleId><ArticleId IdType="pubmed">18191683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N. Engl. J. Med. 2005;353:2643&#x2013;2653. doi: 10.1056/NEJMOA052187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA052187</ArticleId><ArticleId IdType="pmc">PMC2637991</ArticleId><ArticleId IdType="pubmed">16371630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hero C., Rawshani A., Svensson A.M., Franz&#xe9;n S., Eliasson B., Eeg-Olofsson K., Gudbj&#xf6;rnsdottir S. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care. 2016;39:996&#x2013;1003. doi: 10.2337/dc15-2450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-2450</ArticleId><ArticleId IdType="pubmed">27208327</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcovecchio M.L., Chiesa S.T., Bond S., Daneman D., Dawson S., Donaghue K.C., Jones T.W., Mahmud F.H., Marshall S.M., Neil H.A.W., et al. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N. Engl. J. Med. 2017;377:1733&#x2013;1745. doi: 10.1056/NEJMoa1703518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1703518</ArticleId><ArticleId IdType="pubmed">29091568</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries F.M., Kolthof J., Postma M.J., Denig P., Hak E. Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis. PLoS ONE. 2014;9:e111247. doi: 10.1371/journal.pone.0111247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111247</ArticleId><ArticleId IdType="pmc">PMC4220992</ArticleId><ArticleId IdType="pubmed">25372483</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo J., Jeon J., Baek M., Song S.O., Kim J. Impact of statin treatment on cardiovascular risk in patients with type 1 diabetes: A population-based cohort study. J. Transl. Med. 2023;21:806. doi: 10.1186/s12967-023-04691-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04691-6</ArticleId><ArticleId IdType="pmc">PMC10640735</ArticleId><ArticleId IdType="pubmed">37951886</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller M., Stein J., Shuster J., Theriaque D., Samyn M., Pepine C., Silverstein J. Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. J. Pediatr. Endocrinol. Metab. 2009;22:65&#x2013;68. doi: 10.1515/JPEM.2009.22.1.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/JPEM.2009.22.1.65</ArticleId><ArticleId IdType="pmc">PMC3621084</ArticleId><ArticleId IdType="pubmed">19344076</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S., Herder C., Schloot N.C., Koenig W., Heise T., Heinemann L., Kolb H., on behalf of the DIATOR Study Group. Song Y. Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial. PLoS ONE. 2011;6:e17554. doi: 10.1371/journal.pone.0017554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017554</ArticleId><ArticleId IdType="pmc">PMC3055882</ArticleId><ArticleId IdType="pubmed">21412424</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zeeuw D., A Anzalone D., A Cain V., Cressman M.D., Heerspink H.J.L., A Molitoris B., Monyak J.T., Parving H.-H., Remuzzi G., Sowers J.R., et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3:181&#x2013;190. doi: 10.1016/S2213-8587(14)70246-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(14)70246-3</ArticleId><ArticleId IdType="pubmed">25660356</ArticleId></ArticleIdList></Reference><Reference><Citation>Reith C., Preiss D., Blackwell L., Emberson J., Spata E., Davies K., Halls H., Harper C., Holland L., Wilson K., et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: An individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12:306&#x2013;319. doi: 10.1016/S2213-8587(24)00040-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(24)00040-8</ArticleId><ArticleId IdType="pmc">PMC7615958</ArticleId><ArticleId IdType="pubmed">38554713</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano R.P., Cannon C.P., Blazing M.A., Nicolau J.C., Corbal&#xe1;n R., &#x160;pinar J., Park J.-G., White J.A., Bohula E.A., Braunwald E., et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus Without Diabetes Mellitus Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial) Circulation. 2018;137:1571&#x2013;1582. doi: 10.1161/CIRCULATIONAHA.117.030950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.030950</ArticleId><ArticleId IdType="pubmed">29263150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-J., Cho J.Y., You S.C., Yun K.H., Cho Y.-H., Shin W.-Y., Im S.W., Kang W.C., Park Y., Lee S.Y., et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur. Heart J. 2023;44:972&#x2013;983. doi: 10.1093/eurheartj/ehac709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac709</ArticleId><ArticleId IdType="pubmed">36529993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.-K., Hong S.-J., Lee Y.-J., Hong S.J., Yun K.H., Hong B.-K., Heo J.H., Rha S.-W., Cho Y.-H., Lee S.-J., et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet. 2022;400:380&#x2013;390. doi: 10.1016/S0140-6736(22)00916-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00916-3</ArticleId><ArticleId IdType="pubmed">35863366</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunoki K., Nakamura K., Miyoshi T., Enko K., Kohno K., Morita H., Kusano K.F., Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 2011;217:486&#x2013;491. doi: 10.1016/j.atherosclerosis.2011.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2011.04.019</ArticleId><ArticleId IdType="pubmed">21592480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriacks K., Coly G., Krishnaswami S., Patel S.B., Kidambi S. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus. Metab. Syndr. Relat. Disord. 2015;13:84&#x2013;90. doi: 10.1089/met.2014.0114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2014.0114</ArticleId><ArticleId IdType="pubmed">25490061</ArticleId></ArticleIdList></Reference><Reference><Citation>Semova I., Levenson A.E., Krawczyk J., Bullock K., Williams K.A., Wadwa R.P., Shah A.S., Khoury P.R., Kimball T.R., Urbina E.M., et al. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population. J. Clin. Lipidol. 2019;13:940&#x2013;946. doi: 10.1016/j.jacl.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2019.09.008</ArticleId><ArticleId IdType="pmc">PMC6980756</ArticleId><ArticleId IdType="pubmed">31706902</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson A.E., Wadwa R.P., Shah A.S., Khoury P.R., Kimball T.R., Urbina E.M., de Ferranti S.D., Bishop F.K., Maahs D.M., Dolan L.M., et al. PCSK9 Is Increased in Youth with Type 1 Diabetes. Diabetes Care. 2017;40:e85&#x2013;e87. doi: 10.2337/dc16-2563.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-2563</ArticleId><ArticleId IdType="pmc">PMC5481981</ArticleId><ArticleId IdType="pubmed">28588146</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojanin D., Vekic J., Milenkovic T., Vukovic R., Zeljkovic A., Stefanovic A., Janac J., Ivanisevic J., Mitrovic K., Miljkovic M., et al. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Atherosclerosis. 2019;280:14&#x2013;20. doi: 10.1016/j.atherosclerosis.2018.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2018.11.020</ArticleId><ArticleId IdType="pubmed">30453116</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiter L.A., Cariou B., M&#xfc;ller-Wieland D., Colhoun H.M., Del Prato S., Tinahones F.J., Ray K.K., Bujas-Bobanovic M., Domenger C., Mandel J., et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes. Metab. 2017;19:1781&#x2013;1792. doi: 10.1111/dom.13114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13114</ArticleId><ArticleId IdType="pmc">PMC5698740</ArticleId><ArticleId IdType="pubmed">28905478</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes&#x2014;2020. Diabetes Care. 2020;43((Suppl. 1)):S111&#x2013;S134. doi: 10.2337/dc20-S010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-S010</ArticleId><ArticleId IdType="pubmed">31862753</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donoghue M.L., Fazio S., Giugliano R.P., Stroes E.S.G., Kanevsky E., Gouni-Berthold I., Im K., Pineda A.L., Wasserman S.M., &#x10c;e&#x161;ka R., et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk insights from the FOURIER trial. Circulation. 2019;139:1483&#x2013;1492. doi: 10.1161/CIRCULATIONAHA.118.037184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.037184</ArticleId><ArticleId IdType="pubmed">30586750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y.M., Giugliano R.P., Ran X., Deedwania P., De Ferrari G.M., George J.T., Gouni-Berthold I., Lima G.P.d.S., Handelsman Y., Lewis B.S., et al. Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals with Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025;48:1512&#x2013;1516. doi: 10.2337/dc25-0942.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc25-0942</ArticleId><ArticleId IdType="pmc">PMC12368373</ArticleId><ArticleId IdType="pubmed">40544474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner V.A., Szarek M., Aylward P.E., Bhatt D.L., Diaz R., Edelberg J.M., Fras Z., Goodman S.G., Halvorsen S., Hanotin C., et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J. Am. Coll. Cardiol. 2020;75:133&#x2013;144. doi: 10.1016/j.jacc.2019.10.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.10.057</ArticleId><ArticleId IdType="pubmed">31948641</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun H.M., Leiter L.A., M&#xfc;ller-Wieland D., Cariou B., Ray K.K., Tinahones F.J., Domenger C., Letierce A., Israel M., Samuel R., et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc. Diabetol. 2020;19:14. doi: 10.1186/s12933-020-0991-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-0991-1</ArticleId><ArticleId IdType="pmc">PMC7007683</ArticleId><ArticleId IdType="pubmed">32035487</ArticleId></ArticleIdList></Reference><Reference><Citation>Cariou B., Leiter L., M&#xfc;ller-Wieland D., Bigot G., Colhoun H., Del Prato S., Henry R., Tinahones F., Letierce A., Aurand L., et al. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM&#x2013;INSULIN trial. Diabetes Metab. 2017;43:453&#x2013;459. doi: 10.1016/j.diabet.2017.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2017.01.004</ArticleId><ArticleId IdType="pubmed">28347654</ArticleId></ArticleIdList></Reference><Reference><Citation>The ASCEND Study Collaborative Group Effects of n&#x2212;3 Fatty Acid Supplements in Diabetes Mellitus. N. Engl. J. Med. 2018;379:1540&#x2013;1550. doi: 10.1056/NEJMoa1804989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1804989</ArticleId><ArticleId IdType="pubmed">30146932</ArticleId></ArticleIdList></Reference><Reference><Citation>The ORIGIN Trial Investigators n&#x2013;3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N. Engl. J. Med. 2012;367:309&#x2013;318. doi: 10.1056/NEJMoa1203859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1203859</ArticleId><ArticleId IdType="pubmed">22686415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., Doyle R.T., Jr., Juliano R.A., Jiao L., Granowitz C., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med. 2019;380:11&#x2013;22. doi: 10.1056/NEJMoa1812792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1812792</ArticleId><ArticleId IdType="pubmed">30415628</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Cardiology  2019 ESC/EAS Guidelines for Management of Dyslipidemia.  [(accessed on 26 June 2025)].  Available online:  https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/09/12/15/13/2019-esc-eas-guidelines-for-dyslipidaemias.</Citation></Reference><Reference><Citation>ISPAD Clinical Practice Guidelines 2024: Editorial.  [(accessed on 26 June 2025)].  Available online:  https://www.ispad.org/resource/icpcg--editorial-2024-pdf.html.</Citation></Reference><Reference><Citation>De Ferranti S.D., Steinberger J., Ameduri R., Baker A., Gooding H., Kelly A.S., Mietus-Snyder M., Mitsnefes M.M., Peterson A.L., St-Pierre J., et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019;139:E603&#x2013;E634. doi: 10.1161/CIR.0000000000000618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000618</ArticleId><ArticleId IdType="pubmed">30798614</ArticleId></ArticleIdList></Reference><Reference><Citation>Elian V., Popovici V., Ozon E.-A., Musuc A.M., Fi&#x21b;a A.C., Rusu E., Radulian G., Lupuliasa D. Current Technologies for Managing Type 1 Diabetes Mellitus and Their Impact on Quality of Life&#x2014;A Narrative Review. Life. 2023;13:1663. doi: 10.3390/life13081663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13081663</ArticleId><ArticleId IdType="pmc">PMC10456000</ArticleId><ArticleId IdType="pubmed">37629520</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun J.E., Lee S., Lee Y., Ahn J.Y., Kim G., Hur K.Y., Lee M., Jin S., Kim J.H. Continuous glucose monitoring defined glucose variability is associated with cardiovascular autonomic neuropathy in type 1 diabetes. Diabetes Metab. Res. Rev. 2019;35:e3092. doi: 10.1002/dmrr.3092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3092</ArticleId><ArticleId IdType="pubmed">30345631</ArticleId></ArticleIdList></Reference><Reference><Citation>Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T., Bosi E., Buckingham B.A., Cefalu W.T., Close K.L., et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42:1593&#x2013;1603. doi: 10.2337/dci19-0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci19-0028</ArticleId><ArticleId IdType="pmc">PMC6973648</ArticleId><ArticleId IdType="pubmed">31177185</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>